THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Progress Across Sirt6 Patent Portfolio

LONDON, UK / ACCESS Newswire / August 3, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), an emerging leader in the field of longevity research, announces progress across its two principal SIRT6 patent families covering its centenarian-derived SIRT6 variant (SIRT6c; N308K/A313S).

• US patent application covering the use of SIRT6c in NAFLD and NASH published

• Track One prioritized examination granted for the foundational in-licensed US SIRT6 compound of matter patent application

• Corresponding European application at an advanced stage of examination

Dr. Eric Leire, Chief Executive Officer of Genflow Biosciences, commented: "Protecting our centenarian-derived SIRT6 variant remains central to Genflow's strategy. Our foundational SIRT6c family, which is exclusively licensed to Genflow, seeks broad protection for the variant, while our Company-owned MASH family adds indication-specific claims. Progress in the US and Europe, alongside our delivery and muscular-disease filings, advances a layered intellectual property strategy spanning the variant, its delivery and its potential therapeutic applications."

US NAFLD PATENT APPLICATION PUBLISHED

The Company has been informed that the United States Patent and Trademark Office ("USPTO") has published Genflow's patent application US 2026/0199524 A1, entitled "Variants of Sirtuin 6 for the Treatment of Non-Alcoholic Fatty Liver Disease".

The application relates to the use of the Company's centenarian-derived SIRT6 variant (N308K/A313S) in the prevention and/or treatment of non-alcoholic fatty liver disease ("NAFLD"), including non-alcoholic steatohepatitis ("NASH").

The application names Dr. Manlio Vinciguerra and Dr. Eric Leire as inventors and is assigned to Genflow Biosciences Plc.

Publication is a procedural step in the examination process and does not constitute the grant of a patent.

PRIORITIZED EXAMINATION GRANTED FOR FOUNDATIONAL US APPLICATION

The USPTO has granted Track One prioritized examination for the foundational in-licensed US SIRT6 patent application, "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases".

The application forms part of a patent family jointly owned by the University of Rochester, The Trustees of Columbia University in the City of New York and Albert Einstein College of Medicine and exclusively licensed worldwide to Genflow.

Track One status accelerates examination but does not guarantee grant or determine the final scope of any claims that may be allowed.

The foundational patent family is also progressing in other jurisdictions, including Canada, where a request for examination has been filed for application (CA 3218849).

EUROPEAN APPLICATION AT AN ADVANCED STAGE

The corresponding European application (IBIO-1826/EP) is at last stage before the European Patent Office ("EPO"). The Company is currently awaiting a communication under Rule 71(3) EPC. The timing of grant remains subject to completion of the EPO's formal procedures. Further updates will be provided as appropriate.

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic liver disease for which treatment options remain limited and substantial unmet need persists. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Genflow Biosciences PLC